Contact a Lawyer Now
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 17, 2021 to file lead plaintiff applications in a securities class action lawsuit against CytoDyn, Inc. (OTC: CYDY).
CytoDyn and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On March 5, 2021, the Company issued a press release purporting to tout the positive trial results of its product Leronlimab, stating in part, that “the Phase 3 trial of leronlimab for the treatment of severe-to-critical patients with COVID-19 demonstrated continued safety, substantial improvement in the survival rate, and faster hospital discharge in critically ill COVID-19 patients”; however, as subsequently highlighted by industry analysts in the following days, the Company also disclosed that “[a]mongst all patients in mITT, the primary endpoint (all-cause mortality at Day 28) was not statistically significant.”
On this news, shares of CytoDyn plummeted.
If you purchased securities of CytoDyn and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (firstname.lastname@example.org), or fill out the form on this page.
The case is Lewis v. CytoDyn, Inc., No. 3:21-cv-05190.
Click here to read the case complaint.